Application of permeability‐limited physiologically-based pharmacokinetic models: Part II-prediction of p‐glycoprotein mediated drug–drug interactions with digoxin-Reference-Cited by-同舟云学术

Application of permeability‐limited physiologically-based pharmacokinetic models: Part II-prediction of p‐glycoprotein mediated drug–drug interactions with digoxin

Published:2013-09 Issue:9 Volume:102 Page:3161-3173
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Neuhoff Sibylle,Yeo Karen Rowland,Barter Zoe,Jamei Masoud,Turner David B.,Rostami‐Hodjegan Amin

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference77 articles.

1. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug;Fenner;Clin Pharmacol Ther,2009

2. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy;Wacher;Mol Carcinog,1995

3. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics;Wacher;J Pharm Sci,1998

4. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin;Greiner;J Clin Invest,1999

5. Dose-independent pharmacokinetics of digoxin in humans;Ochs;Am Heart J,1978

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates;Journal of Pharmacokinetics and Pharmacodynamics;2023-06-21

2. Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?;CPT: Pharmacometrics & Systems Pharmacology;2022-11-11

3. A permeability‐ and perfusion‐based PBPK model for improved prediction of concentration‐time profiles;Clinical and Translational Science;2022-05-31

4. Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium;Clinical Pharmacology & Therapeutics;2022-05-24

5. APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC AND PHARMACODYNAMIC (PBPK/PD) MODELING COMPRISING TRANSPORTERS;Drug Transporters;2022-04-05